Correct Answer: B. 80 hours
This question tests understanding of first-order elimination kinetics and the concept of half-lives in drug clearance. The patient has digoxin toxicity (nausea, vomiting) with a serum concentration of 4 mg/dL, which is 4 times the therapeutic range (1 mg/dL). To determine when to resume treatment, we must calculate how many half-lives are needed to reduce the serum concentration from 4 mg/dL to the therapeutic range of 1 mg/dL.
Using the principle that each half-life reduces the drug concentration by 50%:
- After 1 half-life (40 hours): 4 → 2 mg/dL
- After 2 half-lives (80 hours): 2 → 1 mg/dL
Therefore, 2 half-lives = 2 × 40 hours = 80 hours is required for the serum concentration to decline from 4 mg/dL to the therapeutic level of 1 mg/dL. This is the standard approach in Indian clinical practice (per KD Tripathi pharmacology) for managing digoxin toxicity. Digoxin has a narrow therapeutic index (0.5–2 mg/dL), and waiting for adequate clearance before resuming is critical to prevent recurrent toxicity. The calculation assumes normal renal function; in elderly Indian patients with renal impairment, clearance may be slower.
Why the other options are wrong
A. 120 hours — This represents 3 half-lives (3 × 40 = 120 hours), which would reduce the concentration to 0.5 mg/dL—below the therapeutic range. While this ensures complete safety, it is unnecessarily prolonged. The question asks for the minimum time to resume treatment, not the time to achieve sub-therapeutic levels. This is an overtreatment trap that wastes clinical time. C. 140–180 hours — This represents 3.5–4.5 half-lives, which would reduce concentration to near-zero levels. This is excessive and clinically impractical. The trap here is confusing the concept of 'complete clearance' with 'therapeutic clearance.' NBE may lure students who think 'safety margin' requires maximum elimination rather than reaching the therapeutic threshold. D. 40 hours — This is only 1 half-life, which reduces the concentration from 4 mg/dL to 2 mg/dL—still twice the therapeutic range. Resuming treatment at this point would result in recurrent toxicity. This is a common student error where the half-life value itself is mistaken for the answer, ignoring the need to calculate the number of half-lives required.
High-Yield Facts
- Digoxin half-life is 40 hours in patients with normal renal function; it increases significantly in renal impairment (up to 5–7 days in severe CKD).
- Therapeutic range of digoxin is 0.5–2 mg/dL (or 0.6–2.6 nmol/L); toxicity typically occurs above 2 mg/dL, especially in hypokalaemia.
- Each half-life reduces drug concentration by 50%; therefore, n half-lives reduce concentration by (1/2)^n.
- Time to reach therapeutic level = number of half-lives needed × t½; in this case, 2 half-lives × 40 hours = 80 hours.
- Digoxin toxicity management includes stopping the drug, correcting electrolytes (especially potassium), and using digoxin-specific antibody fragments (Digibind/DigiFab) in severe cases per Indian guidelines.
Mnemonics
HALF-LIFE RULE FOR DRUG CLEARANCE Each half-life = 50% reduction. To go from 4× to 1× therapeutic level = 2 half-lives. Formula: Time = (log₂ of concentration ratio) × t½ = 1 × 40 = 80 hours. DIGOXIN TOXICITY MEMORY HOOK Digoxin toxicity → Don't resume until Drug drops to therapeutic range. Count half-lives, don't guess. In Indian practice, always check K⁺ and Mg²⁺ levels before restarting.
NBE Trap
NBE pairs a high serum digoxin level with the half-life value itself (40 hours) to trap students who confuse "the half-life of the drug" with "the time to resume treatment." Students must recognize that the question requires calculating how many half-lives are needed, not just stating the half-life.
Clinical Pearl
In Indian hospitals, digoxin toxicity is common in elderly patients with renal impairment and concurrent diuretic use (leading to hypokalaemia). Before resuming digoxin, always check serum potassium, magnesium, and renal function—these factors alter both digoxin clearance and myocardial sensitivity to toxicity.
_Reference: KD Tripathi Pharmacology, Chapter on Cardiac Glycosides; Harrison Principles of Internal Medicine, Chapter 234 (Heart Failure)_